AR128013A1 - Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf - Google Patents

Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf

Info

Publication number
AR128013A1
AR128013A1 ARP220103488A ARP220103488A AR128013A1 AR 128013 A1 AR128013 A1 AR 128013A1 AR P220103488 A ARP220103488 A AR P220103488A AR P220103488 A ARP220103488 A AR P220103488A AR 128013 A1 AR128013 A1 AR 128013A1
Authority
AR
Argentina
Prior art keywords
polypeptide complexes
antigen
binding polypeptide
extracellular domains
complexes containing
Prior art date
Application number
ARP220103488A
Other languages
English (en)
Spanish (es)
Inventor
Heather Dawn Kamp
Edward Seung
Zhi Yang
- Nabel Gary J Yong
Ronnie R Wei
Elias Zerhouni
Original Assignee
Modex Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modex Therapeutics filed Critical Modex Therapeutics
Publication of AR128013A1 publication Critical patent/AR128013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP220103488A 2021-12-17 2022-12-16 Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf AR128013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163291305P 2021-12-17 2021-12-17

Publications (1)

Publication Number Publication Date
AR128013A1 true AR128013A1 (es) 2024-03-20

Family

ID=86773602

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103488A AR128013A1 (es) 2021-12-17 2022-12-16 Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf

Country Status (13)

Country Link
US (1) US20240034808A1 (enExample)
EP (1) EP4448585A4 (enExample)
JP (1) JP2025500918A (enExample)
KR (1) KR20240133797A (enExample)
CN (1) CN118613504A (enExample)
AR (1) AR128013A1 (enExample)
AU (1) AU2022416564A1 (enExample)
CA (1) CA3239979A1 (enExample)
CL (1) CL2024001751A1 (enExample)
IL (1) IL313617A (enExample)
MX (1) MX2024007120A (enExample)
TW (1) TW202330588A (enExample)
WO (1) WO2023114965A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118251411A (zh) * 2021-09-29 2024-06-25 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2025096824A1 (en) * 2023-10-31 2025-05-08 Modex Therapeutics, Inc. Targeted lnp delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914761B2 (en) * 2014-07-10 2018-03-13 Washington University Oligomers for TNF superfamily inhibition
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2018151820A1 (en) * 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CN111315405A (zh) * 2017-11-09 2020-06-19 免疫医疗有限责任公司 双特异性融合多肽及其使用方法
MX2021000307A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
WO2021077132A1 (en) * 2019-10-14 2021-04-22 The University Of Chicago Methods and compositions comprising modified fab scaffolds and protein g fab binding domains

Also Published As

Publication number Publication date
JP2025500918A (ja) 2025-01-15
EP4448585A4 (en) 2026-02-25
CA3239979A1 (en) 2023-06-22
MX2024007120A (es) 2024-08-09
IL313617A (en) 2024-08-01
WO2023114965A3 (en) 2023-08-24
WO2023114965A2 (en) 2023-06-22
CL2024001751A1 (es) 2024-11-29
TW202330588A (zh) 2023-08-01
EP4448585A2 (en) 2024-10-23
AU2022416564A1 (en) 2024-06-27
KR20240133797A (ko) 2024-09-04
US20240034808A1 (en) 2024-02-01
CN118613504A (zh) 2024-09-06

Similar Documents

Publication Publication Date Title
CL2024000896A1 (es) Polipéptidos de unión a antígeno, complejos y métodos de uso de los mismo.
CL2024001751A1 (es) Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf
BR112022001368A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
CL2021001750A1 (es) Receptores quiméricos y metodos de uso de los mismos (divisional solicitud 2677-2020)
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
PE20220231A1 (es) Proteinas de fusion flt3l-fc y metodos de uso
CL2020003127A1 (es) Anticuerpos bispecificos anti-pvrig/anti-tigit y métodos de uso
CL2024002235A1 (es) Anticuerpo anti-cd73 humano; método de producción; composición farmacéutica; y su uso.
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
JOP20230192A1 (ar) جسم مضاد ثلاثي النوعية يستهدف bcma، وgprc5d، وcd3
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
SA521420953B1 (ar) بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1
EA202191457A1 (ru) Анти-pd-l1/анти-4-1bb биспецифические антитела и их применения
MX2024006968A (es) Anticuerpos cdh17 y metodos de tratamiento del cancer.
MX2024003355A (es) Anticuerpos anti-cd3.
CL2016001134A1 (es) Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
BR112021024544A2 (pt) Anticorpo monoclonal anti-ceacam5 e método de preparação do mesmo e uso do mesmo
MX2024010593A (es) Anticuerpos 3e10 humanizados, variantes y fragmento de unión al antígeno de los mismos
PE20240761A1 (es) Proteinas de union a psma y usos de estas
AR128031A1 (es) Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden
BR112023000826A2 (pt) Anticorpo anti-ctla-4 e uso do mesmo
WO2020223392A3 (en) Cancer associated antibody compositions and methods of use
MX2024007393A (es) Complejos polipeptidicos de union a antigeno activados condicionalmente y metodos de uso de los mismos.
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.